According to research, data from trials like STEP 1 and SUSTAIN 8 indicates that approximately 40% of the weight lost by patients taking semaglutide can be attributed to lean mass, primarily muscle tissue, raising concerns about potential cardiovascular and bone health risks due to muscle loss
A JCA conclusion that relative effectiveness versus the EU standard-of-care comparator could not be determined gives national payers cover to delay, discount, or reject reimbursement applications
Many patients drive in from Concord, Lexington, Burlington, and Billerica, or connect through Logan Express before a flight out of Boston
Against HGH (human growth hormone), IGF-1 LR3 produces faster visible changes (muscle fullness within 7 days vs 46 weeks for HGH) but without HGH's fat-mobilizing effects or connective tissue strengthening
Under traditional Medicare Part D plans, coverage for weight loss medications like Zepbound has historically been limited due to Medicare's exclusion of weight loss drugs
Expanding the paradigm for plaque development in Peyronies disease